drugset
drugset / Trial / NCT01420627

EZN-2279 in Patients With ADA-SCID

NCT01420627 ↗

Phase 3 Completed 7 enrolled Leadiant Biosciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.

Timeline

Start
2014-01-24
Primary completion
2018-04-10
Completion
2019-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject ELAPEGADEMASE Protein / enzyme biologic — Intramuscular
Background Adagen Unknown — —

Indications

severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency